Vor Biopharma (VOR) Assets Average (2021 - 2026)

Vor Biopharma (VOR) has 6 years of Assets Average data on file, last reported at $485.4 million in Q1 2026.

• Quarterly Assets Average rose 284.96% year-over-year to $485.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $485.4 million (up 284.96% YoY) and the FY2025 annual result came in at $303.5 million, up 78.0% from the prior year.
• Assets Average improved to $485.4 million in Q1 2026 per VOR's latest filing, from $320.2 million in the prior quarter.
• Across five years, Assets Average topped out at $485.4 million in Q1 2026 and bottomed at $126.1 million in Q1 2025.
• The 5-year median for Assets Average is $215.5 million (2022), against an average of $224.2 million.
• The widest annual swing landed in 2024, when Assets Average sank 45.66%; it then jumped 284.96% in 2026.
• Tracing VOR's Assets Average over 5 years: stood at $252.9 million in 2022, then fell by 16.73% to $210.6 million in 2023, then plunged by 38.53% to $129.4 million in 2024, then jumped by 147.36% to $320.2 million in 2025, then jumped by 51.61% to $485.4 million in 2026.
• Per Business Quant, the three latest VOR Assets Average figures stand at $485.4 million (Q1 2026), $320.2 million (Q4 2025), and $190.8 million (Q3 2025).

Peer Comparison